JUNE 10, 2025 — UTSA researchers in the Max and Minnie Tomerlin Voelcker CIDD Preclinical Pharmacology Core for Accelerated Drug Discovery were recently awarded a competitive grant that will allow ...

One landmark study published in 2019 indicated that, among the 1,000 most commonly used human cell lines in preclinical drug discovery, 62% were of European descent, 29% were of East Asian descent ...

All-in-one kit enables in-house, in vitro profiling of human drug-induced liver injury; Rapid access to CN Bio’s FDA-recognized human DILI assay to optimize and de-risk drug candidate selection ...

Most work using AI in drug development intends to reduce the time and money it takes to bring one drug to market – currently 10 to 15 years and US$1 billion to $2 billion.

With over two decades of experience in CRO services and ten years advancing drug development candidates from TRL3 to TRL5, this close cooperation provides tailored preclinical support, cutting ...

Breakthroughs in the preclinical phase have now progressed into the business end of drug development. bcg, a consultancy, estimates that about 65 ai-inspired molecules are currently in human ...

Psilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006 for Frontotemporal Dementia PR Newswire ORLANDO, Fla. and TAMPA, Fla., June 9, 2025 ...

The development of a state-of-the-art ‘tumour-on-chip’ model has made it possible to faithfully reproduce the complex microenvironment of aggressive pancreatic ductal adenocarcinoma (PDAC).

CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay ...

Strategic agreement underscores Psilera's commitment to advancing PSIL-006 with precision neurology approach Results are expected in Q3 2025 ORLANDO, Fla. and TAMPA, Fla., June 9, 2025 /PRNewswire ...